Phase
Condition
Allergy (Pediatric)
Asthma
Treatment
Omalizumab
JYB1904
Clinical Study ID
Ages 18-75 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Able to provide written informed consent voluntarily;
Aged 18-75 years, weight ≥ 40 kg, male or female;
Diagnosed Allergic asthma.
Exclusion
Exclusion Criteria:
Prior exposure to anti-IgE therapy within 1 year;
Allergic to anti-IgE biologics;
Current smokers, or quit smoking within 1 year;
Combined with other non-allergic diseases that cause IgE elevation;
History of malignancy, autoimmune diseases, Immune complex mediated diseases,Hypereosinophilic syndrome;
Other conditions unsuitable for the trial judged by the investigator.
Study Design
Connect with a study center
Shanghai General Hospital
Shanghai, Shanghai 201203
ChinaSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.